SUNNYVALE, CA, April 16 /CNW/ - Molecular Devices, a division of MDS
Analytical Technologies and a leader in innovative solutions for drug
discovery and life sciences research, today announced a breakthrough with the
launch of a live cell Neurotransmitter Transporter Uptake Assay Kit. With the
introduction of this novel assay, researchers will now have a single tool to
screen for live cell kinetic uptake of the three key neurotransmitters -
dopamine, norepinephrine and serotonin - in a homogeneous, fluorescence-based,
high-throughput screening procedure that eliminates the use of radioactive
tags or labels.
Molecular Devices' Neurotransmitter Transporter Uptake Assay Kit
significantly improves upon current procedures that use radiolabeled
neurotransmitter or transporter inhibitors, both of which require specialized
instrumentation, detect only the assay endpoints, and are encumbered by the
disposal of radioactive materials. This assay can be used in both kinetic and
endpoint modes and is a simple, mix-and-read protocol performed in 96- or
384-well formatted microplates - ideal for use in research, including
applications in high-throughput screening and lead optimization.
"Neurotransmitter transporters have become important pharmaceutical
targets, as they play a key role in depression and neurodegenerative diseases,
such as Alzheimer's and Parkinson's diseases. The ability to monitor live cell
uptake of dopamine, norepinephrine and serotonin neurotransmitters is critical
to better understanding these diseases," said Andy Boorn, President of MDS
Analytical Technologies. "With this assay, researchers now have kinetic and
end-point capability that will reduce their reliance upon radioactive labels."
This new assay, like all Molecular Devices' cell-based assays, utilizes a
masking dye to extinguish extracellular fluorescence. This masking dye
technology has been exclusively licensed by Molecular Devices from Bayer AG
(patent nos. US 6,420,183, US 7,063,952, US 7,138,280 and EP 0906572). The
assay kit also includes a novel proprietary fluorescent dye that mimics the
neurotransmitters dopamine, norepinephrine and serotonin.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 6,200 highly skilled people in 28 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
About MDS Analytical Technologies
MDS Analytical Technologies is a newly established MDS Inc. business unit
and is a world-class organization comprised of two main lines of business. The
Sciex product portfolio offers proven market leadership in mass spectrometry
through its joint ventures with two of the world's leading analytical
instrumentation and life sciences companies, Applied Biosystems, a business of
the Applera Corporation and PerkinElmer Inc. The Molecular Devices product
portfolio is the gold standard in high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life sciences
research. Find out more at www.moleculardevices.com or www.mdssciex.com.
For further information:
For further information: Media: Susan Williams-Clark, Director of
Reagents Marketing, (408) 548-6013, Susan.Clark@moldev.com; Investors: Sharon
Mathers, Senior Vice-President, Investor Relations and External
Communications, MDS Inc., (416) 675-6777 x 34721, email@example.com